Pilot Clinical Performance of a Silicone Hydrogel Lens for Up to Six Nights of Extended Wear
Phase: NA
Conditions: Refractive Errors, Myopia, Hyperopia
Sponsor: Alcon Research



Page 2 of 54
Investigator Agreement:

I have read the clinical study described herein, recognize its confidentiality, and 
agree to conduct the described trial in compliance with Good Clinical Practice 
(GCP), the ethical principles contained within the Declaration of Helsinki, this 
protocol, all applicable regulatory authority regulations, and conditions of approval 
imposed by the reviewing IRB or regulatory authority.

I will supervise all testing of the device involving human subjects and ensure that the 
requirements relating to obtaining informed consent and IRB review and approval 
are met in accordance with applicable local and governmental regulations.

I have read and understand the appropriate use of the investigational product(s) as 
described in the protocol, current Investigator’s Brochure, product information, or 
other sources provided by the Sponsor.

I understand the potential risks and side effects of the investigational product(s).

I agree to maintain adequate and accurate records in accordance with government 
regulations and to make those records available for inspection.

I agree to comply with all other requirements regarding the obligations of clinical 
Investigators and all other pertinent requirements of the Sponsor and government 
agencies.

I agree to ensure that all associates, colleagues, and employees assisting in the 
conduct of the study are informed of their obligations in meeting the above 
commitments.
Have you ever been disqualified as an Investigator by any Regulatory Authority?
No        Yes
Have you ever been involved in a study or other research that was terminated?
No        Yes
If yes, please explain here:
Principal Investigator:
Signature
Date
Name and professional 
position:
Address:
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 3 of 54
Table of Contents
Pilot Clinical Performance of a Silicone Hydrogel Lens for Up to Six Nights of Extended 
Wear.....................................................................................................................................1
Table of Contents .......................................................................................................................3
List of Tables..............................................................................................................................5
List of Figures............................................................................................................................6
1
GLOSSARY OF TERMS ....................................................................................................7
2
LIST OF ACRONYMS AND ABBREVIATIONS ...........................................................11
3
PROTOCOL SUMMARY.................................................................................................13
4
PROTOCOL AMENDMENTS .........................................................................................21
4.1
Amendments......................................................................................................21
5
INTRODUCTION.............................................................................................................22
5.1
Rationale and Background ................................................................................22
5.2
Purpose of the Study..........................................................................................23
5.3
Risks and Benefits.............................................................................................23
6
STUDY OBJECTIVES......................................................................................................24
6.1
Primary Objective..............................................................................................24
6.2
Secondary Objective..........................................................................................24
6.4
Safety Objective ................................................................................................25
7
INVESTIGATIONAL PLAN ............................................................................................25
7.1
Study Design .....................................................................................................25
7.2
Rationale for Study Design ...............................................................................25
7.3
Rationale for Duration of Treatment/Follow-Up...............................................26
7.4
Rationale for Choice of Control Product...........................................................26
7.5
Data Monitoring Committee..............................................................................26
8
STUDY POPULATION ....................................................................................................27
8.1
Inclusion Criteria...............................................................................................27
8.2
Exclusion Criteria..............................................................................................27
8.3
Rescreening of Subjects ....................................................................................29
9
TREATMENTS ADMINISTERED...................................................................................29
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 5 of 54
12.1
Subject Evaluability...........................................................................................46
12.2
Analysis Sets .....................................................................................................46
12.3
Demographic and Baseline Characteristics.......................................................47
12.4
Effectiveness Analyses ......................................................................................47
12.4.1
Analysis of Primary Effectiveness Endpoint(s).................................47
12.4.1.1
Statistical Hypotheses........................................................47
12.4.1.2
Analysis Methods ..............................................................47
12.5
Handling of Missing Data .................................................................................48
12.6
Safety Analyses .................................................................................................48
12.8
Sample Size Justification...................................................................................49
13 DATA HANDLING AND ADMINISTRATIVE REQUIREMENTS ...............................49
13.1
Subject Confidentiality......................................................................................49
13.2
Completion of Source Documents and Case Report Forms..............................50
13.3
Data Review and Clarifications.........................................................................51
13.4
Sponsor and Monitoring Responsibilities .........................................................51
13.5
Regulatory Documentation and Records Retention ..........................................52
13.6
Quality Assurance and Quality Control.............................................................52
14 ETHICS .............................................................................................................................52
15 REFERENCES ..................................................................................................................54
15.1
References Applicable for All Clinical Studies.................................................54
15.1.1
US References Applicable for Clinical Studies.................................54
15.2
References for This Clinical Study....................................................................54
List of Tables
Table 2–1
List of Acronyms and Abbreviations Used in This Protocol ...........................11
Table 3–1
Schedule of Study Procedures and Assessments .............................................18
Table 6–1
Primary Objective(s)........................................................................................24
Table 6–2
Safety Objective...............................................................................................25
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 6 of 54
Table 9–1
Test Product .....................................................................................................29
Table 9–2
Control Product................................................................................................31
List of Figures
Figure 11–1
Categorization of All Adverse Events..............................................................40
Figure 11-2
Categorization of All Serious Adverse Events.................................................40
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 7 of 54
1
GLOSSARY OF TERMS
Names of Test Product
Throughout this document, test product(s) will be referred to 
as 
soft contact lenses or 
contact lenses 
Name of Control Product(s)
CooperVision® BIOFINITY® (comfilcon A) soft contact 
lenses
Adverse Device Effect
(ADE)
Adverse event related to the use of an investigational 
medical device (test product) or control product. Note: This 
definition includes adverse events resulting from insufficient 
or inadequate instructions for use, deployment, 
implantation, installation, or operation; any malfunction; 
and use error or intentional misuse of the test product or 
control product.
Adverse Event (AE)
Any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal 
laboratory findings) in subjects, users or other persons, 
whether or not related to the investigational medical device 
(test product). Note: For subjects, this definition includes 
events related to the test product, the control product, or the 
procedures involved. For users or other persons, this 
definition is restricted to events related to the test product.
Requirements for reporting Adverse Events in the study can 
be found in Section 11.
Anticipated Serious 
Adverse Device Effect
Serious adverse device effect which by its nature, incidence, 
severity, or outcome has been identified in the risk 
management file.
Device Deficiency
Inadequacy of a medical device with respect to its identity, 
quality, durability, reliability, safety, or performance. Note: 
This definition includes malfunctions, use errors, and 
inadequate labeling.
Requirements for reporting Device Deficiencies in the study 
can be found in Section 11.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 8 of 54
Enrolled Subject
Any subject who signs an informed consent form for 
participation in the study.
Interventional Clinical Trial
A research trial that prospectively assigns, whether 
randomly or not, human participants or groups of humans to 
one or more health-related interventions to evaluate the 
effects on health outcomes, and/or a research trial in which 
diagnostic or monitoring procedures beyond standard of care 
are conducted and generate outcomes for use in analysis of 
data.
Investigational Product
Is defined as a preventative (vaccine), a therapeutic (drug or 
biologic), device, diagnostic, or palliative used as a test or 
control product in a clinical trial, including a product with a 
marketing authorization when used or assembled 
(formulated or packaged) in a way different from the 
authorized form, or when used for an unauthorized 
indication, or when used to gain further information about 
the authorized form.
Malfunction
Failure of a medical device to perform in accordance with its 
intended purpose when used in accordance with the 
instructions for use or clinical investigation plan.
Non-Serious Adverse Event
Adverse event that does not meet the criteria for a serious 
adverse event.
Randomized Subjects
Any subject who is assigned a randomized treatment.
Serious Adverse Device 
Effect (SADE)
Adverse device effect that has resulted in any of the 
consequences characteristic of a serious adverse event.
Serious Adverse Event 
(SAE)
Adverse event that led to any of the following:

Death.

A serious deterioration in the health of the subject that 
either resulted in:
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 9 of 54
a. a life-threatening illness or injury.
Note: Life-threatening means that the 
individual was at immediate risk of death from 
the event as it occurred, ie, it does not include 
an event which hypothetically might have 
caused death had it occurred in a more severe 
form.
b. any potentially sight-threatening event or 
permanent impairment to a body structure or a 
body function.
c. in-patient hospitalization or prolonged 
hospitalization.
Note: Planned hospitalization for a pre-
existing condition, without serious 
deterioration in health, is not considered a 
serious adverse event. In general, 
hospitalization signifies that the individual 
remained at the hospital or emergency ward 
for observation and/or treatment (usually 
involving an overnight stay) that would not 
have been appropriate in the physician's office 
or an out-patient setting. Complications that 
occur during hospitalization are adverse 
events. If a complication prolongs 
hospitalization or fulfills any other serious 
criteria, the event is serious. When in doubt as 
to whether “hospitalization” occurred, the 
event should be considered serious.
d. a medical or surgical intervention to prevent 
a) or b). 
e. any indirect harm as a consequence of 
incorrect diagnostic test results when used 
within manufacturer’s instructions for use.

Fetal distress, fetal death, or a congenital abnormality or 
birth defect.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 10 of 54
Refer to Section 11 for additional SAEs.
Significant Non-Serious 
Adverse Event
Is a symptomatic, device-related, non-sight threatening 
adverse event that warrants discontinuation of any contact 
lens wear for greater than or equal to 2 weeks.
Refer to Section 11 for additional Significant Non-Serious 
AEs.
Unanticipated Serious 
Adverse Device Effect
Serious adverse device effect which by its nature, incidence, 
severity, or outcome has not been identified in the risk 
management file.
Use Error
Act or omission of an act that results in a different medical 
device response than intended by manufacturer or expected 
by user. Note: This definition includes slips, lapses, and 
mistakes. An unexpected physiological response of the 
subject does not in itself constitute a use error.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 12 of 54
Abbreviation
Definition
SADE 
Serious adverse device effect
SD
Standard deviation
SiHy 
Silicone hydrogel
SLE
Slit-lamp examination
SOP
Standard operating procedure
US / USA
United States of America
VA 
Visual acuity
vs
Versus 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 13 of 54
3
PROTOCOL SUMMARY
This will be a prospective, randomized, controlled, double-masked, contralateral wear 
clinical trial.
Approximately 3 sites in the US will enroll approximately 36 subjects. Subjects will be 
randomized to wear the test 
lens in one eye and the control Biofinity lens in the other 
eye. Subjects will be expected to attend 3 visits: Screening/Baseline/Dispense, Follow-up
visit next day (Day 2) within 4 hours of awakening (after the first night of sleeping), and a 
Week 1 Follow-up/Exit.
Following randomization during the Screening/Baseline/Dispense Visit, study lenses will be 
dispensed to the subject. All study lenses are to be worn overnight for up to 6 nights. Subjects 
will be expected to wear the study lenses continuously in an extended wear modality. 
 
 
 
 
 
Investigational 
Product Type
Device
Study Type
Interventional
Investigational 
Products
Test Product: 
soft contact lenses
Control Product: CooperVision® BIOFINITY® (comfilcon A) soft 
contact lenses
Purpose and 
Rationale
The purpose of this clinical study is to evaluate the on-eye 
performance of the investigational 
lens compared to the 
commercially available Biofinity lens for up to 6 nights/7 days of 
continuous wear.
Objective
The primary objective is to assess initial safety and performance of 
the 
soft contact lens when worn in an extended wear 
modality (ie, up to 6 nights of continuous wear) as compared to the 
Biofinity soft contact lens.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 15 of 54
Safety

AEs

Biomicroscopy findings

Device deficiencies
Assessments
Effectiveness

VA (Snellen distance) with study lenses
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 16 of 54

Safety

AEs

Biomicroscopy

Device deficiencies
Study Design
This will be a prospective, randomized, controlled, double-masked, 
contralateral clinical trial. Subject participation in the study will be 
approximately 1 week with up to 6 nights/7 days of continuous 
wear.
Subject 
Population
Volunteer subjects aged 18 or over who are adapted soft contact lens 
wearers, excluding Biofinity habitual wearers, have at least 
3 months of soft contact lens wearing experience, and who wear 
their habitual lenses at least 5 days per week and in an extended 
wear modality a minimum of 1 night per week. Subjects must 
require contact lenses in a power range from -1.00 to -6.00 D. 
Pregnant and breastfeeding women are excluded from this study.
Key Inclusion 
Criteria
(See Section 8.1 for 
a complete list of 
inclusion criteria)

Successful wear of spherical soft contact lenses in both eyes 
during the past 3 months for a minimum of 5 days per week and 
in an extended wear modality with minimum of 1 night per 
week. 

Best corrected VA 20/25 or better in each eye.
Key Exclusion 
Criteria
(See Section 8.2 for 
a complete list of 
exclusion criteria)

Any habitual wear of Biofinity contact lenses.
Data Analysis and 
Sample Size 
Justification
No formal hypotheses are formulated for the primary effectiveness 
endpoint of VA; hence no inferential testing will be performed.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 17 of 54
Descriptive summary statistics will be provided on the Snellen 
categories as well as the converted logMAR values. 
 
Given the pilot nature of the study, no formal power calculations 
were completed.
Key Words
 Biofinity, extended wear, 6 nights
 
 
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 21 of 54
4
PROTOCOL AMENDMENTS
Modification of the protocol is prohibited without prior written agreement in the form of a 
protocol amendment. All amendments must be created by the Study Sponsor and must be 
approved by the IRB/IEC and global and regional Health Authorities, as applicable, prior to 
implementation except when required to mitigate immediate safety risks or when the changes 
involve only logistical or administrative revisions.
Amendments may necessitate that the informed consent and other study-related material be 
revised. If the consent form is revised, all subjects currently enrolled in the study must sign 
the approved, revised informed consent (re-consent), as required by the IRB/IEC.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 24 of 54
and through close supervision by a licensed clinician during exposure to the study lenses. In 
general, the risks with 
are anticipated to be similar to the marketed control soft 
contact lenses.
There may also be unknown risks with the use of 
 Any risk to subjects in this clinical 
study will be minimized by compliance with the eligibility criteria and study procedures, 
clinical oversight, and monitoring. Site personnel will educate subjects on proper hygiene and 
lens handling, and compliance with the use of contact lenses according to the protocol. 
Subjects should be instructed not to wear contact lenses while swimming due to increased 
risk of infection. Site personnel should advise the subjects to remove contact lenses and 
return for prompt follow-up of symptoms such as ocular discomfort, foreign body sensation, 
excessive tearing, vision changes, or hyperemia.
Refer to the IB for additional information.
6
STUDY OBJECTIVES
6.1
Primary Objective
The primary objective is to assess performance of the 
soft contact lens when worn in 
a continuous wear modality (ie, up to 6 nights/7 days of continuous wear) as compared to the 
Biofinity soft contact lens.
Table 6–1
Primary Objective(s)
Objective(s)
Endpoint(s)
Evaluate VA of the investigational 
 
soft contact lens compared to the 
commercially available Biofinity soft 
contact lens.
Primary Effectiveness 

Distance VA (Snellen) with study 
lenses
6.2
Secondary Objective
Not applicable.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 25 of 54
6.4
Safety Objective
Table 6–2
Safety Objective
Objective
Endpoints
Initial evaluation of the safety profile of the 
test lens.
AEs
Biomicroscopy findings 
Device deficiencies
7
INVESTIGATIONAL PLAN
7.1
Study Design
This will be a prospective, randomized, controlled, double-masked, contralateral wear 
clinical trial.
Approximately 3 sites in the US will enroll approximately 36 subjects. Subjects will be 
randomized to wear the test 
 lens in one eye and the control Biofinity lens in the 
other eye. Subjects will be expected to attend 3 visits: Screening/Baseline/Dispense, Follow-
up visit next day (Day 2) within 4 hours of awakening (after the first night of sleeping), and a 
Week 1 Follow-up/Exit visit.
Following randomization during the Screening/Baseline/Dispense Visit, study lenses will be 
dispensed to the subject. All study contact lenses are to be worn overnight for up to
6 nights/7 days of continuous wear. Subjects will be expected to wear the study lenses 
continuously in an extended wear modality. 
 
. 
 
 
The total study investigation is expected to take approximately 1 month.
7.2
Rationale for Study Design
Extended wear contact lenses have been marketed and tested in the United States and Europe 
since the 1970s. The advantage of day and night lens wear without having the need for 
removal for cleaning and disinfection everyday has been appealing to many contact lens 
wearers. For successful overnight lens wear, the lenses must not only be safe and effective 
but also be comfortable over the prescribed wearing period.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 27 of 54
8
STUDY POPULATION
The study population consists of adult subjects with non-diseased eyes, who require optical 
correction for refractive ametropia. It is aimed to enroll approximately 36 subjects in 
approximately 3 sites (US). Estimated time needed to recruit subjects for the study is 
approximately 3 weeks. The intended study population consists of volunteer subjects aged 
18 or over who are adapted soft contact lens wearers, excluding Biofinity habitual wearers, 
have at least 3 months of soft contact lens wearing experience, and who wear their habitual 
lenses at least 5 days per week and in an extended wear modality a minimum of 1 night per 
week. Subjects must require contact lenses in a power range from -1.00 to -6.00 D. 
8.1
Inclusion Criteria
Written informed consent must be obtained before any study specific assessment is 
performed. Upon signing informed consent, the subject is considered enrolled in the study.
Subjects eligible for inclusion in this study must fulfill all of the following criteria:
1.
Subject must be at least 18 years of age.
2.
Subject must be able to understand and sign an IRB/IEC approved Informed Consent 
form.
3.
Willing and able to attend all scheduled study visits as required per protocol.
4.
Successful wear of spherical soft contact lenses in both eyes during the past 3 months 
for a minimum of 5 days per week and in an extended wear modality at least 1 night 
per week.
5.
Manifest cylinder ≤ 0.75 D in each eye.
6.
Best corrected (using manifest refraction) VA 20/25 or better in each eye.
7.
Requiring contact lens sphere power from -1.00 to -6.00 D.
8.
Willing and able to use contact lens cleaning products, as needed.
8.2
Exclusion Criteria
Subjects fulfilling any of the following criteria are not eligible for participation in this study:
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 28 of 54
1.
Any anterior segment infection, inflammation, or abnormality or disease (including 
systemic) that contraindicates contact lens wear, as determined by the Investigator.
2.
Any use of systemic or ocular medications for which contact lens wear could be 
contraindicated, as determined by the Investigator.
3.
History of ocular or intraocular surgery, including refractive surgery for which 
contact lens extended wear could be contraindicated, as determined by the 
Investigator and/or history of irregular cornea.
4.
Current or previous orthokeratology treatment or has worn RGP lenses in the past 
12 months.
5.
Biomicroscopy findings at screening that are moderate (Grade 3) or higher and/or 
corneal vascularization that is mild (Grade 2) or higher; or presence of corneal 
infiltrate(s).
6.
Current or history of pathologically dry eye in either eye that, in the opinion of the 
Investigator, would preclude contact lens wear.
7.
Current or history of herpetic keratitis in either eye.
8.
Eye injury in either eye within 12 weeks immediately prior to enrollment for this 
trial.
9.
Current or history of intolerance, hypersensitivity or allergy to any component of 
study lenses, 
10.
Any habitual wear of Biofinity contact lenses.
11.
Any use of habitual/prescribed topical ocular medications or artificial tear or 
rewetting drops (habitual) that would require instillation during study lens wear.
12.
Currently pregnant or breast-feeding.
13.
The Investigator, his/her staff, family members of the Investigator, family members 
of the Investigator’s staff, or individuals living in the households of the 
aforementioned persons may not participate in the study.
14.
Participation of the subject in a clinical trial within the previous 30 days or currently 
enrolled in any clinical trial.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 29 of 54
15.
Monovision contact lens wearers.
8.3
Rescreening of Subjects
Rescreening of subjects is not allowed in this study.
9
TREATMENTS ADMINISTERED
9.1
Investigational Products
Extra replacement lenses will not be given to the subject upon leaving the site. In the event a 
lens needs to be replaced, the subject must return to the site for a replacement lens. 
Test Product:
soft contact lenses
Control Product:
CooperVision® BIOFINITY® (comfilcon A) soft 
contact lenses
Table 9–1
Test Product
Test Product
soft contact lenses (LID018869) (
Manufacturer
Alcon Laboratories, Inc.
6201 South Freeway
Fort Worth, Texas 76134-2099
USA
Indication for Use 
and Intended 
Purpose in the 
Current Study 
The intended use of this contact lens is for vision correction.
Product Description 
and Parameters 
Available for this 
Study


Water content: 55% ± 2% (target)

Power range: -1.00 to -6.00 D (0.25 D steps)

Base curve: 8.4 (±0.2 mm) (target)

Diameter: 14.2 mm (±0.2 mm) (target)
Formulation
Silicone Hydrogel. Additional details can be found in the IB.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 30 of 54
Usage

Wear:
o
Up to 6 nights/7 days of continuous wear
o
Contralateral

Exposure: up to 1 week 
 

Additional details can be found in the Manual of Procedures
Number/Amount of 
Product to be 
Provided to the 
Subject
Only one test lens will be dispensed to the subject on Visit 1.
Packaging 
Description
Blister foil pack 
Labeling 
Description

Lens Foil label includes:
-
material name and/or identifier
-
base curve
-
diameter
-
manufacturing protocol number
-
packing solution
-
power
-
lot number
-
expiration date
-
content statement
-
investigational device statement
-
Sponsor information

Provided in packages of up to 20 lenses per power per box, 
identified with the following:
-
a color-coded label stating the protocol number
-
material identifier
-
power
-
an investigational use only statement
-
tracking number
Storage Conditions
Stored at room temperature.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 31 of 54
Supply
All test lenses will be provided to the site. The site will dispense the 
test lens to each subject at Visit 1.
Table 9–2
Control Product
Control Product
CooperVision® BIOFINITY® (comfilcon A) soft contact lenses
Manufacturer
CooperVision
Indication for Use
The intended use of this contact lens is for vision correction.
Product Description 
and Parameters 
Available for this 
Study

Material: comfilcon A

Water content: 48%

Power range: -1.00 to -6.00 D (0.25 D steps)

Base curve: 8.6 mm

Diameter: 14.0 mm
Formulation
Silicone Hydrogel. Additional details can be found in the Biofinity 
package insert.
Usage

Wear:
o
Up to 6 nights/7 days of continuous wear
o
Contralateral

Exposure: up to 1 week

 

Additional details can be found in the Manual of Procedures
Number/Amount of 
Product to be 
Provided to the 
Subject
Only one control lens will be dispensed to the subject on Visit 1.
Packaging 
Description
Blister foil pack in commercial packaging.
Labeling 
Description
Commercial labeling.
Storage Conditions
Stored at room temperature.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 32 of 54
Supply
Site will procure control lenses locally. The site will dispense the 
control lens to each subject at Visit 1.
 
 
9.3
Treatment Assignment / Randomization
Subjects will be randomized in a 1:1 ratio to receive treatment with 
or Biofinity in 
one eye and the other lens in the fellow eye, as indicated below:
Sequence 1: 
(OD)/Biofinity (OS)
Sequence 2: Biofinity (OD)/
(OS)
Only after signing the ICF, a subject will be assigned a subject number by the electronic data 
capture system. 
A randomization list will be generated using a validated system that automates the random 
assignment of treatment arms to randomization numbers in the specified ratio. Subjects will 
be assigned a treatment (lens sequence) according to the randomization list uploaded in the 
randomization system. The randomization list will be generated and maintained by the Study 
Sponsor.
At Visit 1, all eligible subjects will be randomized via the EDC/randomization integration
system to one of the lens sequences. The Investigator’s delegate will access the respective 
system after confirming that the subject meets all the eligibility criteria. A randomization 
number will be automatically assigned to the subject according to the subject randomization 
list, but will not be communicated to the site user. The EDC/randomization integration 
system will inform the site user of the treatment (lens sequence) assignment to be dispensed 
to the subject.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 35 of 54

All unused products (supplied by the Study Sponsor) are available for return to the Study 
Sponsor, as directed

Any study lenses associated with a device deficiency or with any product-related AE (ie, 
ADE or SADE) are returned to the Study Sponsor for investigation, unless otherwise 
directed by the Sponsor. Refer to Section 11 of this protocol for additional information on 
the reporting of device deficiencies and AEs. Refer to the MOP for the return of study 
products associated with these events.
The Investigator is responsible for proper disposition of all unused IPs at the conclusion of 
the study, according to the instructions provided in the MOP.
9.6
Changes to Concomitant Medications, Treatments/Procedures
After the subject is enrolled into the study, the Investigator must instruct the subject to notify 
the study site about:

Any new medications 

Alterations in dose or dose schedules for current medications

Any medical procedure or hospitalization that occurred or is planned

Any non-drug therapies (including physical therapy and blood transfusions)
The Investigator must document this information in the subject’s case history source 
documents.
10 STUDY PROCEDURES AND ASSESSMENTS
Subjects will be expected to attend 3 office visits, as shown below.
Visit #
Visit Type
Visit Day
Visit Window
Visit 1
Screening / Baseline /
Dispense
Day 1
N/A
Visit 2
Next Day Follow-up
Day 2
≤ 4 hours after awakening
Visit 3
Week 1 Follow-up / 
Exit
Day 7
7 days (-1 day) of lens wear (ideally 
within 4 hours of awakening)
Unscheduled Visits and Early Termination Visits are allowed, if necessary.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 36 of 54
At the Screening/Baseline/Dispense Visit, study lenses will be dispensed for contralateral 
wear to the subject. All study lenses will be worn in an extended wear modality for up to
6 nights. Problem lenses (if any) will not be discarded but collected by the subject and 
returned to the investigational site.
 
. VA will be measured at all visits, and 
any decrease of 2 or more lines from the Dispense Visit to any follow-up visit should be 
explained by the Investigator. 
 
10.1 Informed Consent and Screening
The Investigator or delegate must explain the purpose and nature of the study, and have the 
subject read, sign, and date the IRB/IEC-approved informed consent document. The subject 
must sign the ICF BEFORE any study-specific procedures or assessments can be performed, 
including study-specific screening procedures. Additionally, have the individual obtaining 
consent from the subject and a witness, if applicable, sign and date the informed consent 
document. 
10.2 Description of Study Procedures and Assessments
Detailed descriptions of assessments and procedures are provided in the MOP. The 
Investigator is responsible for ensuring responsibilities for all procedures and assessments are 
delegated to appropriately qualified site personnel.
10.2.1 Demographics
Obtain demographic information including age, race, ethnicity, and sex.
10.2.2 Medical History and Concomitant Medications
Collect medical history information, including information on all medications used within the 
past 30 days. Include herbal therapies, vitamins, and all over-the-counter as well as 
prescription medications. Throughout the subject’s participation, obtain information on any 
changes in medical health and/or the use of concomitant medications.
10.2.3 Investigational Product Compliance
Review subject compliance with the study lens usage and adjunct product usage and collect 
all foils from used and unused study IPs and other products that were dispensed.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 37 of 54
10.2.4 Adverse Event Collection: Safety Assessment
Assess and record any AEs that are observed or reported, including those associated with 
changes in concomitant medication dosing since the previous visit. Requirement for reporting 
AEs can be found in Section 11.
10.2.5 Slit-Lamp Biomicroscopy: Safety Assessment
SLE must be performed in both eyes before instillation of any diagnostic eye drops.
10.2.6 Device Deficiencies: Safety Assessment
Assess and record any device deficiencies that are reported or observed. Requirements for 
reporting device deficiencies in the study can be found in Section 11.
10.3 Unscheduled Visits
If a subject visit occurs between any regularly scheduled visits, this visit must be documented 
as an Unscheduled Visit. If the subject is discontinuing from the study, this will be 
documented as Early Exit, not an Unscheduled Visit. During all unscheduled visits, the 
Investigator must conduct the following procedures: 

Collect AE information

Record changes in medical condition or concomitant medication

Collect device deficiency information, as applicable

Assess and record VAs

Perform biomicroscopy (assessments with or without lenses, as applicable)
The Investigator may perform additional procedures for proper diagnosis and treatment of the 
subject according to Table 3–1. The Investigator must document this information in the 
subject’s case history source documents.
If during an Unscheduled Visit the subject is discontinuing the IP or discontinuing from the 
study, the Investigator must conduct Exit procedures according to Table 3–1, as possible.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 38 of 54
10.4 Discontinued Subjects
10.4.1 Screen Failures
Screen failures are subjects who were excluded from the study after signing the informed 
consent, not meeting the inclusion/exclusion criteria, and prior to randomization to 
product/dispense of study product. 
The Investigator must document the reason for screen failure in the subject’s case history 
source documents.
Subject numbers must not be re-used.
10.4.2 Discontinuations
Discontinued subjects are individuals who voluntarily withdraw or are withdrawn from the 
study by the Investigator after signing the informed consent, including screen failures. 
Subject numbers of discontinued subjects must not be re-used.
Subjects may discontinue from the study or study treatment at any time for any reason. 
Subjects may also be discontinued from study treatment at any time if, in the opinion of the 
Investigator, continued treatment poses a risk to their health.
For subjects discontinuing from the study, the Investigator must complete all Exit procedures 
according to Table 3–1, if the subject is willing and able, and if in the opinion of the 
Investigator it is safe for the subject to do so.
The Investigator must document the reason for study or treatment discontinuation in the 
subject’s case history source documents.
To ensure the safety of all subjects who discontinue early, Investigators must assess each 
subject and, if necessary, advise them of any therapies and/or medical procedures that may be 
needed to maintain their health.
10.4.3 Schedule of Procedures and Assessments for Subjects Discontinued 
from Investigational Product 
Other than screen failures, if a subject discontinues from the study, the subject should 
undergo an Early Exit Visit. Refer to Table 3–1.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 39 of 54
10.5 Clinical Study Termination
The Study Sponsor reserves the right to close the investigational site or terminate the study in 
its entirety at any time.
If the clinical study is prematurely terminated or suspended by the Study Sponsor: 

The Study Sponsor must:
o
Immediately notify the Investigator(s) and subsequently provide 
instructions for study termination.
o
Inform the Investigator(s) and the regulatory authorities of the 
termination/suspension and the reason(s) for the termination/suspension. 

The Investigator(s) must:
o
Promptly notify the IRB/IEC of the termination or suspension and of the 
reasons. 
o
Provide subjects with recommendations for post-study treatment options 
as needed.
The Investigator may terminate the site’s participation in the study for reasonable cause.
10.5.1 Follow-Up of Subjects After Study Participation Has Ended 
Following this study, the subject will return to their eye care professional for their routine eye 
care.
11 ADVERSE EVENTS AND DEVICE DEFICIENCIES
11.1 General Information
An AE is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users, or other persons, 
whether or not related to the investigational medical device (test article). Refer to the 
Glossary of Terms and figures below for categories of AEs and SAEs.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 41 of 54
Serious Adverse Events
In addition to reporting all AEs (serious and non-serious) meeting the definitions, the 
Investigator must report any occurrence of the following as an SAE:

An ocular infection including a presumed infectious ulcer with any of the following
characteristics*:
o
Central or paracentral location
o
Penetration of Bowman’s membrane
o
Infiltrates > 2 mm diameter
o
Iritis
o
Increase in intraocular pressure
o
Culture positive for microorganisms
o
Increasing size or severity at subsequent visits

Any central or paracentral corneal event (such as neovascularization) that results in
permanent opacification

Hypopyon

Hyphema

Neovascularization within the central 6 mm of the cornea

Permanent vision loss as defined by loss of 2 or more lines of BCVA from enrollment
visit that fails to resolve

Uveitis (anterior, intermediate, or posterior)

Corneal abrasion affecting ≥ 50% of corneal surface area
*NOTE: Culture samples (from the subject’s eyes, lenses, etc) must be taken [as described in
the MOP; and documented in the narrative section(s) of the corresponding ADE-SAE eCRF],
for any suspected ocular infection, including infiltrates with overlying epithelial defect.
Significant Non-Serious Adverse Events
A significant non-serious AE is a device-related, non-sight threatening AE that warrants 
discontinuation of any contact lens wear for greater than or equal to 2 weeks. In addition, the 
Investigator must report any occurrence of the following as a Significant Non-Serious 
Adverse Event:
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 42 of 54

Peripheral non-progressive non-infectious ulcers

All symptomatic corneal infiltrative events

Corneal staining score greater than or equal to Grade 3 (Refer to MOP for grading scales)

Temporary vision loss as defined by loss of 2 or more lines of BCVA from enrollment
visit that persists for 2 or more weeks

Neovascularization score greater than or equal to Grade 2 (Refer to MOP for grading
scales)
The above events are based upon the categories provided in the ISO 11980 and the US FDA 
Premarket Notification (510(k)) Guidance Document for Daily Wear Contact Lenses.
Device Deficiencies
A device deficiency is inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety, or performance. A device deficiency may or may not be 
associated with patient harm (ie, ADE or SADE); however, not all ADEs or SADEs are due 
to a device deficiency. The Investigator should determine the applicable category listed in the 
Device Deficiency eCRF for the identified or suspect device deficiency and report any 
patient harm separately. Examples of device deficiencies include the following: 

Failure to meet product specifications (eg, incorrect lens power/diameter/base
curve/color)

Lens cloudy

Lens surface/edge defect

Torn lens during handling/in pack

Packaging deficit (eg, mislabeled product)

Suspect product contamination

Lack of performance
11.2 Monitoring for Adverse Events
At each visit, after the subject has had the opportunity to spontaneously mention any 
problems, the Investigator should inquire about AEs by asking the standard questions:

“Have you had any health problems since your last study visit?”

“Have there been any changes in the medicines you take since your last study visit?”
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 43 of 54
Changes in any protocol-specific parameters and/or questionnaires evaluated during the 
study are to be reviewed by the Investigator. Any untoward (unfavorable and unintended) 
change in a protocol-specific parameter or questionnaire response that is clinically relevant, 
in the opinion of the Investigator, is to be reported as an AE. These clinically relevant 
changes will be reported regardless of causality. 
11.3 Procedures for Recording and Reporting
AEs are collected from the time of informed consent. Any pre-existing medical conditions or 
signs/symptoms present in a subject prior to the start of the study (ie, before informed 
consent is signed) are not considered AEs in the study and should be recorded in the Medical 
History section of the eCRF.
In addition, temporary lens awareness or visual changes during the fitting process are not 
considered AEs if the Investigator assesses that the symptom(s) can reasonably resolve within 
the anticipated adaptation period. For each recorded event, the ADE and SAE documentation 
must include: date of occurrence, severity, treatment (if applicable), outcome, and 
assessments of the seriousness and causality. In addition, the Investigator must document all 
device deficiencies reported or observed with test and control products on the Device 
Deficiency eCRF. The site must submit all available information on ADEs, SAEs, and device 
deficiencies to the Study Sponsor immediately as follows:

ADEs or SAEs are documented on the Serious Adverse Event and Adverse Device Effect 
eCRF within 24 hours of the Investigator’s or site’s awareness.

Device deficiencies are documented on the Device Deficiency eCRF within 24 hours of 
the Investigator’s or site’s awareness.

A printed copy of the completed Serious Adverse Event and Adverse Device Effect and/or 
Device Deficiency eCRF must be included with product returns.

Additional relevant information after initial reporting must be entered into the eCRF as 
soon as the data become available.

Document any changes to concomitant medications on the appropriate eCRFs.

Document all relevant information from Discharge Summary, Autopsy Report, Certificate 
of Death, etc, if applicable, in narrative section of the Serious Adverse Event and Adverse 
Device Effect eCRF.
Note: Should the EDC system become non-operational, the site must complete the 
appropriate paper Serious Adverse Event and Adverse Device Effect and/or Device Deficiency
Form. The completed form is emailed to the Study Sponsor at msus.safety@alcon.com
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 44 of 54
according to the timelines outlined above; however, the reported information must be entered 
into the EDC system once it becomes operational.
 
 
 
Study Sponsor representatives may be contacted for any protocol related question and their 
contact information is provided in the MOP that accompanies this protocol.
Further, depending upon the nature of the AE or device deficiency being reported, the Study 
Sponsor may request copies of applicable portions of the subject’s medical records. The 
Investigator must also report all AEs and device deficiencies that could have led to a SADE 
according to the requirements of regulatory authorities or IRB/IEC.
Intensity and Causality Assessments
Where appropriate, the Investigator must assess the intensity (severity) of the AE based upon 
medical judgment with consideration of any subjective symptom(s), as defined below:
Intensity (Severity)
Mild
An AE is mild if the subject is aware of but can easily tolerate the sign or 
symptom.
Moderate
An AE is moderate if the sign or symptom results in discomfort significant 
enough to cause interference with the subject’s usual activities.
Severe
An AE is severe if the sign or symptom is incapacitating and results in the 
subject’s inability to work or engage in their usual activities.
For every AE in the study, the Investigator must assess the causality (Related or Not Related 
to the medical device or study procedure). An assessment of causality will also be performed 
by Study Sponsor utilizing the same definitions, as shown below:
Causality
Related
An AE classified as related may be either definitely related or possibly related 
where a direct cause and effect relationship with the medical device or study 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 45 of 54
procedure has not been demonstrated, but there is a reasonable possibility that 
the AE was caused by the medical device or study procedure.
Not Related
An AE classified as not related may either be definitely unrelated or simply 
unlikely to be related (ie, there are other more likely causes for the AE).
The Study Sponsor will assess the AEs and may upgrade the Investigator’s assessment of 
seriousness and/or causality. The Study Sponsor will notify the Investigator of any AEs that 
are upgraded from non-serious to serious or from unrelated to related.
Additionally, the Study Sponsor shall immediately conduct an evaluation of any 
unanticipated adverse device effect, including anticipated adverse events that occur in 
unanticipated severity or frequency. The results of this evaluation will be reported to the
FDA, the IRB, and participating Investigators within 10 working days upon receiving 
notification of the effect.
11.4 Return Product Analysis
Investigational product associated with device deficiencies and/or product related AEs [ie, 
ADE or SADE] will be returned for investigation as detailed in the MOP.
11.5 Unmasking of the Study Treatment
Masked information on the identity of the assigned medical device should not be disclosed 
during the study. If the treatment code needs to be broken in the interest of subject safety, the 
Investigator is encouraged to contact an appropriate Study Sponsor representative prior to 
unmasking the information if there is sufficient time. Dependent upon the individual 
circumstances (ie, medical emergency), the code may be broken prior to contact with the 
Study Sponsor. The Study Sponsor must be informed of all cases in which the code was 
broken and of the circumstances involved. Additionally, the Study Sponsor may be required 
to unmask the information in order to fulfill expedited regulatory requirements.
11.6 Follow-Up of Subjects with Adverse Events 
The Investigator is responsible for adequate and safe medical care of subjects during the 
study and for ensuring that appropriate medical care and relevant follow-up procedures are 
maintained after the study. 
The Investigator should provide the Study Sponsor with any new safety information (which 
includes new AEs and changes to previously reported AEs) that may affect the safety 
evaluation of the device. For AEs that are unresolved/ongoing at time of subject exit from 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 46 of 54
study, any additional information received at follow-up should be documented in the eCRFs 
up to study completion (ie, database lock). 
Any additional data received up to 1 month after subject discontinuation or exit must be 
documented and available upon the Study Sponsor’s request. All complaints received after 
this time period will be considered and processed as spontaneous (following the postmarket 
vigilance procedures) and should be communicated to the medical device’s manufacturer as 
per local requirements, as applicable.
The Investigator should also report complaints on non-Alcon products directly to the 
manufacturer as per the manufacturer’s instructions or local regulatory requirements.
11.7 Pregnancy in the Clinical Study
Pregnancy is not reportable as an AE; however, complications may be reportable and will be 
decided on a case–by-case basis. Should a woman become pregnant during study 
participation, the pregnancy will be recorded on source documentation.
If a subject becomes pregnant, the subjects may also be discontinued from study treatment at 
any time if, in the opinion of the Investigator, continued treatment poses a risk to their health.
12 ANALYSIS PLAN
Continuous variables will be summarized using the number of observations, mean, standard 
deviation (SD), median, minimum, and maximum. Categorical variables will be summarized 
with counts and percentages from each category. Any deviations to the analysis plan will be 
updated during the course of the study as part of a protocol amendment or will be detailed in 
the clinical study report.
12.1 Subject Evaluability
Final subject evaluability must be determined prior to breaking the code for masked 
treatment (lens sequence) assignment and locking the database, based upon the Deviations 
and Evaluability Plan.
12.2 Analysis Sets
Only 1 analysis set will be defined, namely the safety analysis set. It will include all eyes 
exposed to any study lenses evaluated in this study. 
Eyes will be analyzed based upon the lens exposed at the time of the clinical assessment. 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 47 of 54
12.3 Demographic and Baseline Characteristics
Demographic information will be presented by lens sequence and overall.
12.4 Effectiveness Analyses
12.4.1 Analysis of Primary Effectiveness Endpoint(s)
The primary objective of this study is to assess initial safety and performance of the 
soft contact lens when worn in an extended wear modality (ie, up to 6 nights/7 days of 
continuous wear) as compared to the Biofinity soft contact lens. 
The primary endpoint is distance VA with study lenses, collected for each eye.
12.4.1.1 Statistical Hypotheses
No hypothesis testing of the primary effectiveness endpoint is planned.
12.4.1.2 Analysis Methods
Summary statistics will be provided.
 

Listing for VA changes from Dispense of 2 or more lines during the study
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 48 of 54
 
 
12.5 Handling of Missing Data
All data obtained in evaluable subjects/eyes will be used. No imputation for missing values
will be carried out.
12.6 Safety Analyses
The safety endpoints are:

AEs

Biomicroscopy findings

Device deficiencies
There are no safety hypotheses planned in this study. The focus of the safety analysis will be
a comprehensive descriptive assessment of occurrence of AE as well as the other listed 
parameters.
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 49 of 54
Descriptive summaries (counts and percentages) for ocular and nonocular AEs will be
presented by Medical Dictionary for Regulatory Activities Preferred Terms. A listing 
containing details of the AEs will also be provided.
Each biomicroscopy parameter will be tabulated by its grade.
Frequency for each device deficiency category will be presented and a supporting listing will
be provided.
12.8 Sample Size Justification
Given the early pilot nature of the study, sample size/power calculation is not relevant.
13 DATA HANDLING AND ADMINISTRATIVE REQUIREMENTS
13.1 Subject Confidentiality
The Investigator must ensure that the subject’s anonymity is maintained throughout the 
course of the study. In particular, the Investigator must keep an enrollment log with 
confidential identifying information that corresponds to the subject numbers and initials of 
each study participant. At the end of the clinical study, the Study Sponsor will collect a copy 
of the enrollment log without any identifying subject information. All documents submitted 
to the Study Sponsor will identify the subjects exclusively by number and demographic 
information. No other personally identifying information will be transmitted to the Study 
Sponsor.
 
 
 
 
 
 
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 50 of 54
13.2 Completion of Source Documents and Case Report Forms
The nature and location of all source documents will be identified to ensure that original data 
required to complete the CRFs exist and are accessible for verification by the site monitor, 
and all discrepancies shall be appropriately documented via the query resolution process. Site
monitors are appointed by the Study Sponsor and are independent of study site staff.
If electronic records are maintained, the method of verification must be determined in
advance of starting the study. 
At a minimum, source documents include the following information for each subject:

Subject identification (name, sex, race/ethnicity)

Documentation of subject eligibility

Date of informed consent

Dates of visits

Documentation that protocol specific procedures were performed

Results of study parameters, as required by the protocol

IP accountability records

Documentation of AEs and other safety parameters (if applicable)

Records regarding medical histories and the use of concomitant therapies prior to and 
during the study

Date of study completion and reason for early discontinuation, if applicable
It is required that the author of an entry in the source documents be identifiable. Direct access 
to source documentation (medical records) must be allowed for the purpose of verifying that 
the data recorded on the CRF are consistent with the original source data.
Only designated individuals at the site will complete the CRFs. The CRFs must be completed 
at regular intervals following the clinical study visit schedule. It is expected that all data 
reported have corresponding entries in the source documents. The Principal Investigator is 
responsible for reviewing and certifying that the CRFs are accurate and complete. The only 
subject identifiers recorded on the CRFs will be subject number, and subject demographic 
information. 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 51 of 54
13.3 Data Review and Clarifications
A review of CRF data to the subject’s source data will be completed by the site monitor to 
ensure completeness and accuracy. After the CRFs have been completed, additional data 
clarifications and/or additions may be needed as a result of the data cleaning process. Data 
clarifications are documented and are part of each subject’s CRF.
13.4 Sponsor and Monitoring Responsibilities
The Study Sponsor will designate a monitor to conduct the appropriate site visits at the 
appropriate intervals according to the study monitoring plan. The clinical investigation will 
be monitored to ensure that the rights and well-being of the subjects are protected, the 
reported data are accurate, complete, and verifiable from the source documents, and the study 
is conducted in compliance with the current approved protocol (and amendments[s], if 
applicable), with current GCP, and with applicable regulatory requirements.
The site may not screen subjects or perform the informed consent process on any subject
until it receives a notification from an appropriate Study Sponsor representative that the site 
may commence conducting study activities. Monitoring will be conducted periodically while 
the clinical study is ongoing. Monitoring methods may include site visits, telephone, written,
and fax correspondence. Close-out visits will take place after the last visit of the last subject
at the site.
A Coordinating Investigator may be identified by the Study Sponsor to review and endorse 
the final study report. In cases where a Coordinating Investigator is engaged, the Study 
Sponsor will select the Coordinating Investigator based upon their experience, qualifications, 
active study participation, and their willingness and availability to take on this role.
 
 
 
 
 
 
 
 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 52 of 54
13.5 Regulatory Documentation and Records Retention
The Investigator is required to maintain up-to-date, complete regulatory documentation as 
indicated by the Study Sponsor and the Investigator’s files will be reviewed as part of the 
ongoing study monitoring. Financial information is to be kept separately. 
Additionally, the Investigator must keep study records and source documents consistent with 
the terms of the clinical study agreement with the Study Sponsor. If the Investigator retires, 
relocates, or for any other reason withdraws from responsibility of keeping the study records, 
then the Study Sponsor must be notified and suitable arrangements made for retention of 
study records and source documents needed to comply with national and international 
regulations.
13.6 Quality Assurance and Quality Control
The Study Sponsor will secure agreement from all involved parties to ensure direct access to 
all study related sites, source data and documents, and reports for the purpose of monitoring 
and auditing by the Study Sponsor, and inspection by domestic and foreign regulatory 
authorities. Quality control will be applied to each stage of data handling to ensure that all 
data are reliable and have been processed correctly. Agreements made by the Study Sponsor 
with the Investigator/Institution and any other parties involved in the clinical study will be 
provided in writing as part of the protocol or as a separate agreement.
14 ETHICS
This clinical study must be conducted in accordance with the ethical principles contained 
within: 

The Declaration of Helsinki, and in compliance with the ICH E6 GCP Consolidated 
Guideline, ISO 14155:2011, and the applicable US FDA 21 CFR Regulations. 

SOPs of the Study Sponsor and contract research organizations participating in the 
conduct of the clinical study and all other applicable regulations. 

Notifications and timelines for reporting protocol deviations should be based upon
applicable Ethics Committee requirements
The Investigator must ensure that all personnel involved in the conduct of the study are 
qualified to perform their assigned responsibilities through relevant education, training, and 
experience. The Investigator and all clinical study staff must conduct the clinical study in 
compliance with the protocol. Deviations from this protocol, regulatory requirements, and/or 
GCP must be recorded and reported to the Sponsor prior to database lock. If needed, 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 53 of 54
corrective and preventive action should be identified, implemented, and documented within 
the study records. Use of waivers to deviate from the clinical protocol is prohibited.
Before clinical study initiation, this protocol, the informed consent form, any other written 
information given to subjects, and any advertisements planned for subject recruitment must 
be approved by an IRB/IEC. The Investigator must provide documentation of the IRB/IEC 
approval to the Study Sponsor. The approval must be dated and must identify the applicable 
protocol, amendments (if any), informed consent form, assent form (if any), all applicable 
recruiting materials, written information for subject, and subject compensation programs. The 
IRB/IEC must be provided with a copy of the IB, any periodic safety updates, and all other 
information as required by local regulation and/or the IRB/IEC. At the end of the study, the 
Investigator must notify the IRB/IEC about the study’s completion. The IRB/IEC also must 
be notified if the study is terminated prematurely. Finally, the Investigator must report to the 
IRB/IEC on the progress of the study at intervals stipulated by the IRB/IEC.
Voluntary informed consent must be obtained in writing from every subject and the process 
shall be documented before any procedure specific to the clinical investigation is applied to 
the subject. The Investigator must have a defined process for obtaining consent. Specifically, 
the Investigator, or their delegate, must explain the clinical study to each potential subject and 
the subject must indicate voluntary consent by signing and dating the approved informed 
consent form. The subject must be provided an opportunity to ask questions of the 
Investigator, and if required by local regulation, other qualified personnel. The Investigator 
must provide the subject with a copy of the consent form written in a language the subject 
understands. The consent document must meet all applicable local laws and provide subjects 
with information regarding the purpose, procedures, requirements, and restrictions of the 
study, along with any known risks and potential benefits associated with the IP and the study, 
the available compensation, and the established provisions for maintaining confidentiality of 
personal, protected health information. Subjects will be told about the voluntary nature of 
participation in the study and must be provided with contact information for the appropriate 
individuals should questions or concerns arise during the study. The subject also must be told 
that their records may be accessed by appropriate authorities and Sponsor-designated 
personnel. The Investigator must keep the original, signed copy of the consent (file in 
subject’s medical records) and must provide a duplicate copy to each subject according to 
local regulations. 
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

Page 54 of 54
15 REFERENCES
15.1 References Applicable for All Clinical Studies

ISO 11980:2012 Ophthalmic optics - Contact lenses and contact lens care products -
Guidance for clinical investigations

ISO 14155:2011 Clinical investigation of medical devices for human subjects - Good 
clinical practice
15.1.1 US References Applicable for Clinical Studies

21 CFR Part 11 - Electronic Records; Electronic Signatures

21 CFR Part 50 - Protection of Human Subjects

21 CFR Part 56 - Institutional Review Boards

21 CFR Part 812 - Investigational Device Exemptions

21 CFR Part 54 - Financial Disclosure by Clinical Investigators

The California Bill of Rights
15.2 References for This Clinical Study
US FDA Premarket Notification (510(k)) Guidance Document for Daily Wear Contact Lenses
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020

                                                                                                                
                                                                                     
Alcon - Business Use Only 
 
Effective Date:  
Document:  
Version:  
Status:  
Printed By: 
Print Date:  
Effective
2.0; Most-Recent; Effective; CURRENT
TDOC-0056933
Protocol - Clinical
14-May-2020